A systematic review on the off-label use of montelukast in atopic dermatitis treatment

• Published in: International journal of clinical pharmacy Vol. 40; no. 5; pp. 963 - 976
• Main Authors: Chin, Weng Khong, Lee, Shaun Wen Huey
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.10.2018; Springer Nature B.V
• Subjects: Acetates - therapeutic use; Atopic dermatitis; Dermatitis; Dermatitis, Atopic - diagnosis; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - immunology; Eczema; Humans; Immunosuppressive Agents - therapeutic use; Inflammation; Internal Medicine; Leukotriene Antagonists - therapeutic use; Medicine; Medicine & Public Health; Montelukast; Off-Label Use; Pharmacy; Population studies; Pruritus; Quinolines - therapeutic use; Randomized Controlled Trials as Topic - methods; Review Article; Reviews; Skin; Leukotriene receptor antagonists; Systemic therapy; Montelukast; Off-label use; Atopic dermatitis; Eczema

Background Atopic dermatitis (AD) is the most common form of eczema. As leukotriene mediators are involved in the inflammatory phase of atopic dermatitis, montelukast has been suggested as a possible therapy. Aim of the review To evaluate the safety and efficacy of montelukast off-label use for the ...